Skip to content Skip to search

Republish This Story

* Please read before republishing *

We’re happy to make this story available to republish for free under an Attribution-NonCommercial-NoDerivatives Creative Commons license as long as you follow our republishing guidelines, which require that you credit The 19th and retain our pixel. See our full guidelines for more information.

To republish, simply copy the HTML at right, which includes our tracking pixel, all paragraph styles and hyperlinks, the author byline and credit to The 19th. Have questions? Please email [email protected].

— The Editors

Loading...

Modal Gallery

/
Donate to our newsroom

Menu

Topics

  • Abortion
  • Politics
  • Education
  • LGBTQ+
  • Caregiving
  • Environment & Climate
  • Business & Economy
View all topics

The 19th News(letter)

News that represents you, in your inbox every weekday.

You have been subscribed!

Please complete the following CAPTCHA to be confirmed. If you have any difficulty, contact [email protected] for help.

Submitting...

Uh-oh! Something went wrong. Please email [email protected] to subscribe.

This email address might not be capable of receiving emails (according to Bouncer). You should try again with a different email address. If you have any questions, contact us at [email protected].

  • Latest Stories
  • Our Mission
  • Our Team
  • Ways to Give
  • Search
  • Contact
Donate
Home

We’re an independent, nonprofit newsroom reporting on gender, politics and policy. Read our story.

Topics

  • Abortion
  • Politics
  • Education
  • LGBTQ+
  • Caregiving
  • Environment & Climate
  • Business & Economy
View all topics

The 19th News(letter)

News that represents you, in your inbox every weekday.

You have been subscribed!

Please complete the following CAPTCHA to be confirmed. If you have any difficulty, contact [email protected] for help.

Submitting...

Uh-oh! Something went wrong. Please email [email protected] to subscribe.

This email address might not be capable of receiving emails (according to Bouncer). You should try again with a different email address. If you have any questions, contact us at [email protected].

  • Latest Stories
  • Our Mission
  • Our Team
  • Ways to Give
  • Search
  • Contact

We’re an independent, nonprofit newsroom reporting on gender, politics and policy. Read our story.

The 19th News(letter)

News that represents you, in your inbox every weekday.

You have been subscribed!

Please complete the following CAPTCHA to be confirmed. If you have any difficulty, contact [email protected] for help.

Submitting...

Uh-oh! Something went wrong. Please email [email protected] to subscribe.

This email address might not be capable of receiving emails (according to Bouncer). You should try again with a different email address. If you have any questions, contact us at [email protected].

Become a member

The 19th thanks our sponsors. Become one.

Abortion

A federal judge could soon block access to an abortion pill. Here’s what that means.

The ruling on mifepristone could come as soon as Friday, and could force abortion providers across the country to adopt a less-effective medical protocol.

Protesters hold up signs during an abortion-rights rally in Austin, Texas.
Protesters hold up signs during an abortion-rights rally in Austin, Texas in June 2022. (Sergio Flores/Getty Images)

Shefali Luthra

Reproductive Health Reporter

Published

2023-02-07 12:55
12:55
February 7, 2023
pm

Republish this story

Share

  • Bluesky
  • Facebook
  • Email

Republish this story

We’re answering the “how” and “why” of abortion news. Subscribe to our daily newsletter.

A federal court in Texas could this week block access to mifepristone, a major drug used for managing abortions. The ramifications of this decision — including blocking future distribution of the drug — would be felt across the country.

Mifepristone was approved in 2000 by the Food and Drug Administration. But a lawsuit filed in Texas this past November argues that the courts should revoke that approval. Legal experts have criticized the case’s arguments, noting that there is no precedent for undoing federal approval for a drug that has been on the market for 23 years. But many anticipate the judge — the conservative Matthew J. Kacsmaryk, who was appointed by former President Donald Trump — to issue a ruling that would do just that. A decision in the case could come as early as this Friday.

The 19th thanks our sponsors. Become one.

Mifepristone is one of two medications used to induce a medication abortion, the most common method of terminating a pregnancy, as well as to manage miscarriages. People who get a medication abortion take mifepristone, followed 24 to 48 hours later by the second medication, misoprostol. Taken together, the combination is incredibly effective and safe to complete from home, which has contributed to its growing popularity.

The mifepristone-misoprostol regimen is also the most effective way for people to manage a miscarriage. But because of federal restrictions on which health care providers can prescribe mifepristone, many people who experience miscarriages already cannot receive that drug. 

The immediate impact of the decision depends on the substance of the ruling. Any ruling would likely be appealed by the losing side, and the relevant appeals courts — the conservative U.S. Court of Appeals for the 5th Circuit and the Supreme Court — have a history of upholding abortion restrictions. Now, many abortion providers and advocates worry that Kacsmaryk will declare a nationwide injunction on mifepristone’s FDA approval, a decision that could halt distribution of the drug across the country.

  • More abortion coverage
    Sen. Mazie Hirono speaks into a microphone on Capitol Hill.
  • Senators ask mifepristone manufacturer to list miscarriage as a use for abortion pill
  • Two major pharmacies say they plan to offer medication abortions. Here’s what that could mean.
  • Americans don’t know if abortion is legal in their state, new poll shows

“There will be a lot of lawyering to figure out whether his injunction is proper, or whether the FDA has authority to nonetheless allow this drug despite the injunction,” said David Cohen, a professor at Drexel University’s Kline School of Law who has studied medication abortion law. “On the possibility that it is legally binding and mifepristone is removed, at least temporarily, it would be a real blow to abortion access.”

A national injunction would impact access to medication abortion treatment in every state, including those where abortion rights are protected. But certain states would likely be hit harder than others, said Elizabeth Nash, who tracks state policy for the Guttmacher Institute, a think tank that studies reproductive health. 

In particular, she singled out states such as Colorado, Pennsylvania and New Mexico, which have become critical access points for abortion access. Clinics in those states have seen particularly large numbers of out-of-state patients in the seven months since Roe v. Wade was overturned. All also have sizable shares of patients who are seeking medication as their preferred method of abortion and who receive that care through telemedicine — a method of care that is also easier for capacity-strapped clinics to provide.  

If distribution of mifepristone is blocked, “we’re going to see a real crunch in capacity,” Nash said.

A potential ban on misoprostol wouldn’t halt medication abortions altogether. In places where mifepristone is unavailable — the majority of countries, given the drug’s relatively high price — many clinicians perform medication abortions using only misoprostol, a regimen that is also safe and effective, but, per most studies, has a slightly higher failure rate than the combination of mifepristone and misoprostol. One study published this week found that misoprostol alone had an 88 percent effectiveness rate among close to 1,000 Americans; mifepristone and misoprostol together are between 95 and 99 percent effective.

Abortion providers across the United States are preparing to shift to misoprostol-only abortions. But preparing large clinic networks — largely staffed by physicians who have provided the two-medication regimen for decades — will be a large and difficult undertaking, and may take some time to fully get off the ground.

A family physician waits to consult with another doctor before a surgical abortion.
A family physician waits to consult with another doctor before a surgical abortion at the Center for Reproductive Health clinic in June 2022 in Albuquerque, New Mexico. (Gina Ferazzi/Los Angeles Times/Getty Images)

“There are misoprostol-only protocols that are well studied, and safe, and effective and will provide a path forward if this injunction goes into place,” said Dr. Kristina Tocce, medical director for Planned Parenthood Rocky Mountains, which operates in Colorado, New Mexico and southern Nevada. 

Still, she said, “any shift in clinical care is challenging in a large agency.”

Some physicians aren’t sure if they would immediately have to stop providing mifepristone, or if they would be permitted to dispense whatever remaining medication they have in stock, including to patients who may be sitting in their clinics when a decision comes. 

And many health care providers aren’t yet comfortable with the nuances of providing misoprostol-only abortions, said Ushma Upadhyay, an associate professor at the University of California San Francisco. She is part of a cohort of reproductive health experts putting together clinical guidelines for American doctors if they need to perform misoprostol-only abortions. 

“This decision will impact people in every state,” she said.

Misoprostol-only abortions also can have more intense side effects than a combination regimen, Upadhyay said, meaning some patients will have to decide if they want to take the pills in their home state, where it is outlawed, or if they want to take them before traveling home, navigating severe cramps and even vomiting while making an hours-long drive or flight.

And because misoprostol only has a higher failure rate, patients traveling out of state could face other risks. If they return home and learn the abortion has failed, multiple experts said, patients may not know where or how to find safe care in their home states, or may need to make another expensive trip across state lines. 

An injunction would not affect providers’ ability to offer surgical abortions, which can also terminate a pregnancy. But those can take more time to perform, can cost providers more to offer and demand more knowledge from health care providers — putting new strains on an abortion network already stretched thin by the fallout from overturning Roe. 

Sign up for more news and context delivered to your inbox, daily

You have been subscribed!

Please complete the following CAPTCHA to be confirmed. If you have any difficulty, contact [email protected] for help.

Submitting…

Uh-oh! Something went wrong. Please email [email protected] to subscribe.

This email address might not be capable of receiving emails (according to Bouncer). You should try again with a different email address. If you have any questions, contact us at [email protected].

Preview of the daily newsletter from The 19th

“It’s really hard as a provider to know there’s a medication that works better than other options and not be able to offer that because of politics,” said Dr. Kristyn Brandi, an abortion provider in New Jersey and board chair for the advocacy group Physicians for Reproductive Health.

The confusion over changing options could potentially turn patients away. Research already shows that patients are often confused about what abortion options are legally available to them. Polling published last week from the Kaiser Family Foundation showed that about half already did not know if they could legally access mifepristone, including in states where abortion is legal. 

This case could exacerbate that. Even if misoprostol-only abortions are available, multiple physicians said, reading about a nationwide injunction could convince patients that they are unable to access medication abortions. That confusion, Brandi said, is likely to grow if and as the case continues to navigate the federal court systems — leaving both patients and physicians unsure about what they can legally do. 

“It’s going to be chaos and chaos for quite a bit,” she said. 

Republish this story

Share

  • Bluesky
  • Facebook
  • Email

Recommended for you

People stand outside of a courthouse.
Federal judges issue conflicting rulings in a pill used for medication abortion
An exam table is seen at a Planned Parenthood Health Center in Louisville, Kentucky.
If mifepristone is blocked, access to medication abortion pills could vary by state — or even by clinic
Demonstrators rally in support of abortion rights at the Supreme Court in Washington, D.C.
Federal judges seem open to restricting access to mifepristone abortion pill
supreme court building on a cloudy day
The 19th Explains: How the Supreme Court could further limit abortion

The 19th News(letter)

News that represents you, in your inbox every weekday.

You have been subscribed!

Please complete the following CAPTCHA to be confirmed. If you have any difficulty, contact [email protected] for help.

Submitting...

Uh-oh! Something went wrong. Please email [email protected] to subscribe.

This email address might not be capable of receiving emails (according to Bouncer). You should try again with a different email address. If you have any questions, contact us at [email protected].

Become a member

Explore more coverage from The 19th
Abortion Politics Education LGBTQ+ Caregiving
View all topics

Our newsroom's Spring Member Drive is here!

Learn more about membership.

  • Transparency
    • About
    • Team
    • Contact
    • Privacy Policy
    • Community Guidelines
  • Newsroom
    • Latest Stories
    • 19th News Network
    • Podcast
    • Events
    • Careers
    • Fellowships
  • Newsletters
    • Daily
    • Weekly
    • The Amendment
    • Event Invites
  • Support
    • Ways to Give
    • Sponsorship
    • Republishing
    • Volunteer

The 19th is a reader-supported nonprofit news organization. Our stories are free to republish with these guidelines.